Science Corporation

1.1 Identity, Mission, and Founding

Science Corporation is a clinical-stage neural engineering company incorporated in 2021 and headquartered in Alameda, California. Co-founded by Max Hodak — who previously co-founded and served as president of Neuralink until May 2021 — and Alan Mardinly, PhD, a Harvard neurobiology PhD and former Neuralink research leader, the company was built around the thesis that the brain, as the body's sole non-transplantable organ, represents the ultimate frontier of medicine. Science's near-term commercial vehicle is PRIMA, a photovoltaic subretinal brain-computer interface (BCI) retinal prosthesis targeting advanced geographic atrophy (GA) from age-related macular degeneration. Beyond PRIMA, the company is simultaneously developing a biohybrid neural interface architecture designed to grow engineered neurons on chips for superior brain integration, a Science Eye optogenetic platform for broader vision restoration, and a MEMS semiconductor foundry in Research Triangle Park, North Carolina, providing in-house manufacturing capability. The founding team elected to remain private and pre-commercial while building a multi-modality neural interface portfolio, staging external product launches around regulatory milestones. Company communications consistently frame the mission as engaging the brain directly as an information-processing organ to achieve effect sizes unreachable by conventional medicine. [CO001, CO002, CO003, CO004, CO005, CO014]

1.2 PRIMA Technology and Product Platform

PRIMA is a photovoltaic subretinal implant approximately 2 × 2 mm in footprint and only 30 µm thick — about half the diameter of a human hair. The device functions as an artificial photoreceptor: the tiny wireless chip, embedded beneath the retina at the photoreceptor layer, converts near-infrared light projected onto it into localized electrical stimulation of the underlying bipolar cells, reintroducing the retinal signal pathway in patients whose photoreceptors have been destroyed by geographic atrophy. The PRIMA system comprises three components: the subretinal implant, specialized glasses containing an embedded camera and infrared projector, and an AI-powered pocket processor that captures the visual scene, identifies salient objects, and directs patterned infrared light to the implant. Because the implant is powered wirelessly by the projected light, no internal battery is required — a key safety and longevity advantage. The photovoltaic retinal stimulation technology was originally developed at Stanford University by Professor Daniel Palanker's laboratory. Science acquired all PRIMA intellectual property and three ongoing clinical trials from Pixium Vision SA of France in April 2024, after Pixium was placed into liquidation proceedings in the Paris Commercial Court. The acquired trial package included the PRIMAvera pivotal study (NCT04676854) and two feasibility trials. Science is now expanding the PRIMA clinical program to include Stargardt disease and retinitis pigmentosa, two leading causes of inherited retinal vision loss in young adults. Current PRIMA prosthetic vision is black-and-white with relatively low resolution; Science has disclosed that the next device generation will optimize visual performance through digital image processing. [CO006, CO007, CO008, CO009, CO010, CO011]

1.3 Leadership and Governance

Science's executive team is led by co-founders with Neuralink pedigrees supplemented by commercial hires added ahead of the PRIMA regulatory endgame. Max Hodak, CEO and co-founder, previously co-founded and served as president of Neuralink before departing in May 2021 to establish Science Corporation. Alan Mardinly, PhD, co-founder and Chief Scientific Officer (appointed December 2025), brings a Harvard neurobiology PhD and over 15 years of neuroscience research experience including prior leadership roles at Neuralink. Darius Shahida, appointed Chief Strategy Officer in December 2025, previously helped raise over $1 billion at Butterfly Network, providing directly applicable large-scale medtech commercialization experience. Frank Brodie, MD, was appointed Medical Director for Vision and PRIMA in December 2025, taking ownership of the U.S. clinical and regulatory pathway. Ralf Hornig, PhD, directs clinical affairs, having prior European BCI program experience. Matthias Wagner leads biohybrid device development. Board composition has not been publicly disclosed; no formal succession plan or key-person insurance for the CEO position has been publicly confirmed. Key-person concentration is highest in Max Hodak, who holds the scientific vision, investor relationships, regulatory strategy, and primary media spokesperson roles. [CO002, CO003, CO023, CO036, CO043, CO044]

1.4 Funding History, Investors, and Valuation

Science Corporation has raised approximately $490 million across four known financing events since its 2021 founding. A Series A of approximately $47.3 million was closed in July 2021, followed by a Series B of approximately $113 million in November 2022. A $104 million convertible note led by Khosla Ventures was raised in approximately April 2025, likely timed to bridge toward the NEJM publication milestone and CE Mark submission. The flagship $230 million Series C was closed in March 2026, with participation from Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT (the venture arm of the U.S. intelligence community), and Quiet Capital — all pre-existing investors — in a round that was oversubscribed with demand exceeding capital requirements. The Series C implies a post-money valuation of approximately $1.5 billion, making Science one of the most highly capitalized private BCI companies globally at this stage. Capital is earmarked for PRIMA's European commercialization, manufacturing scale-up, and advancement of pipeline programs including the biohybrid neural interface and Vessel perfusion platform. The company has publicly stated its imperative is to "become the first BCI company to scale and achieve profitability." Full investor lists for the Series A and B remain undisclosed. [CO016, CO017, CO018, CO019, CO020, CO021]

1.5 Clinical Evidence, Regulatory Status, and Risk Profile

The PRIMAvera pivotal trial (NCT04676854) enrolled 38 patients at 17 sites across France, Germany, Italy, the Netherlands, Spain, and the United Kingdom. All participants had advanced geographic atrophy with no residual central vision. Results published in The New England Journal of Medicine on October 20, 2025, authored by Frank Holz (University Hospital of Bonn, lead), José-Alain Sahel (University of Pittsburgh), and 14 co-authors, demonstrated: 80% of participants achieved meaningful visual acuity improvement at 12 months; 84.4% regained the ability to read letters, numbers, and words; and the mean visual acuity gain was approximately 25.5 letters (more than five lines) on the ETDRS chart. The Data Safety Monitoring Board concluded that benefits outweigh surgical risks. No significant loss of natural peripheral vision was observed. Nineteen patients experienced adverse events including elevated intraocular pressure, retinal tears, and bleeding; the majority resolved within two months. Science submitted a CE Mark application to the European Union in June 2025, applied for U.S. FDA regulatory approval in June 2025, and holds an FDA Breakthrough Device designation originally granted to Pixium in April 2023 and inherited via the April 2024 acquisition. A European commercial launch is anticipated in 2026, which would make Science the first BCI company with a vision-restoring product on market. The U.S. FDA decision remains pending as of mid-2026. Material risks include: PRIMA currently delivers only black-and-white prosthetic vision at relatively low resolution, not natural color sight; pricing and reimbursement terms are undisclosed; the 38-patient trial size may be seen as limited for broad label extensions; longer-term safety data beyond 12 months is still being collected; and the company remains entirely pre-revenue and dependent on continued investor funding through the regulatory and commercial launch process. [CO024, CO025, CO026, CO027, CO028, CO029]

2.1 Market Boundaries and Definition

Science Corporation's PRIMA system addresses a precisely bounded market distinct from the broader ophthalmology, AMD pharmacological, and general BCI landscapes. The included spend is the surgical device system for restoring visual function in end-stage degenerative retinal disease — specifically photovoltaic subretinal implants, associated external hardware, and implantation procedures. Excluded is the pharmacological AMD treatment market (anti-VEGF injections, complement inhibitors, AREDS supplements), optical correction, low-vision aids, gene therapies, and cortical visual prostheses that bypass the retina entirely. The status-quo comparator for advanced geographic atrophy is watchful monitoring with no restorative option: no pharmacological therapy currently restores central vision lost to GA, making PRIMA's clinical comparator natural history rather than a competing drug. Wet AMD pharmacological treatment (anti-VEGF) is adjacent but orthogonal — anti-VEGF injections generate more than 6 million US procedures annually but target a fundamentally different disease stage and mechanism, and patients who progress to end-stage GA are beyond the benefit window of anti-VEGF. PRIMA's closest adjacencies are other retinal implant approaches targeting RP and Stargardt, emerging gene therapies for inherited retinal diseases, and cortical visual prostheses for patients with damaged retinal-optic pathways. The larger BCI neuroprosthetics TAM ($168.27B invasive BCI TAM per Grand View Research) inflates addressable market narratives and should be excluded from PRIMA-specific sizing, as it encompasses motor-function BCIs, communication devices, neuromodulation, and other non-ophthalmological applications. The AMD drug market ($12.64B in 2025) should similarly be treated as context, not PRIMA's market, since it targets a different disease stage. [CM025, CM043, CM024, CM038, CM040]

2.2 Disease Burden and Addressable Patient Population

The primary target indication for PRIMA is advanced geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Approximately 1 million patients in the United States and 5–8 million globally live with GA, with 160,000 new US cases annually. GA disproportionately affects older adults: prevalence is 0.28% at ages 60–64 but rises to 0.98% at ages 70–74, and global AMD prevalence is projected to reach 288 million by 2050 as populations age. In the four largest European markets alone — Germany (400,000–450,000), France (265,000), Italy (170,000), and Spain (155,000) — GA affects over 1 million additional patients, constituting a significant European commercial opportunity if reimbursement can be secured. Beyond GA, Science has expanded PRIMA clinical development into inherited retinal diseases (IRDs). Retinitis pigmentosa affects approximately 1 in 4,000 individuals worldwide, with 80,000–110,000 patients in the US; roughly 12% develop advanced disease with severe vision loss (counting fingers or hand motion only), representing the implant-candidacy tier. Stargardt disease, the most common juvenile macular dystrophy, affects approximately 1 in 8,000–10,000 individuals globally, with earlier onset creating a distinct and younger surgical-candidate demographic. Combined, the three primary indications yield a US patient pool of approximately 1.2 million with end-stage retinal degeneration — but surgical candidacy requirements, including residual retinal function, intact bipolar-cell layer, and health thresholds for surgery, narrow the implantable population considerably below these epidemiological totals. GA accounts for approximately 20% of all AMD-related legal blindness, underscoring the severity tier PRIMA addresses. [CM001, CM002, CM003, CM004, CM005, CM006]

2.3 Market Sizing: Multiple Lenses and Contradictory Estimates

Market sizing estimates for retinal prosthetics vary dramatically by perimeter, methodology, and analyst, making a single TAM figure misleading. Mordor Intelligence, using a narrow definition focused on active device units, values the global retinal implants market at $56.53 million in 2025, growing to $61.28 million in 2026 and $91.72 million by 2031 at an 8.4% CAGR. Insight Partners, using a broader retinal prosthetics perimeter that includes legacy devices, reports $392.53 million in 2025 growing to $922.5 million by 2034 at 11.27% CAGR — a 7× discrepancy for ostensibly the same market and year. Neither analyst publicly discloses the precise scope differences, and the inconsistency should be treated as a limitation of all published retinal prosthetics market estimates. For context, the AMD pharmacological market (anti-VEGF drugs, complement inhibitors) was $12.64 billion in 2025 and projected at $13.58 billion in 2026, roughly 200× larger than even the broadest retinal implant estimate. The broader BCI market overall (Grand View Research: $397.59M non-invasive SOM, $168.27B invasive TAM) encompasses far more than vision applications and should not be used as a PRIMA proxy. A rough bottom-up patient- population SAM for PRIMA, based on ~1M US GA patients at a 2–5% near-term surgical adoption rate and a $50,000–$100,000 per-system average selling price, yields a potential US ceiling SAM of $1B–$5B — but this is a far-future ceiling with no near-term commercial relevance given the nascent reimbursement environment and the 3–5 year post-approval ramp required. The contradictions in published estimates and the absence of validated PRIMA-specific sizing represent a material evidence gap that diligence should surface. [CM009, CM010, CM011, CM012, CM013, CM036]

2.4 Buyer, User, and Payer Segmentation

Science's PRIMA system involves three distinct market roles. The buyer — in the procedural sense — is the retina surgeon or specialized ophthalmic center that selects the technology, trains on its implantation, and integrates it into the clinical workflow. The user is the patient with advanced GA, RP, or Stargardt. The payer is Medicare, private insurance, or a national health service. Budget ownership for initial capital expenditure sits with the hospital or surgical center, while per-patient reimbursement — once established — flows from payers. In the US, advanced GA predominantly affects the Medicare-eligible population (age 65+), making Medicare the dominant payer. RP and Stargardt patients are younger and rely on commercial insurance or, in some cases, Medicaid, with some rare-disease pathways potentially relevant for IRD indications. Hospitals account for 54.5% of the global retinal implants end- user market in 2025 (Mordor Intelligence), with specialty ophthalmic clinics growing at 11.42% CAGR. North America holds 39.75% global market share. RP accounts for 46.95% of the current retinal implants market by disease indication — a signal of what is currently commercially viable, not necessarily a ceiling. Geographic concentration of procedure capacity matters: subretinal implantation requires retina surgeons with specific training, concentrating initial adoption at academic medical centers, which limits volume in the early commercial phase. [CM020, CM021, CM022, CM023, CM042]

2.5 Growth Drivers and Adoption Constraints

The principal market driver for PRIMA is the absence of any approved vision-restoring therapy for advanced GA: the clinical comparator is natural history, and any degree of functional restoration represents a meaningful advance for patients. Aging demographics structurally expand the eligible pool as AMD is strongly age-related. GA progression is relentless — a majority of diagnosed patients lose substantial vision within 2–3 years — creating clinical urgency that drives patient motivation if a safe and reimbursed option exists. Regulatory tailwinds include the FDA's Breakthrough Device Designation pathway reducing review cycles for visual prosthetics, and cost-of-illness analyses estimating $13.5–$32 billion annual burden of inherited retinal diseases in North America that support payer economic cases. Tele-ophthalmology is expanding the geographic reach of retinal implant candidate screening beyond major centers. However, material adoption constraints are real. Subretinal implantation is a complex specialized surgery requiring centers with trained retina surgeons, concentrating procedures at academic settings and throttling community roll-out. The Second Sight Argus II failure — in which more than 350 patients were abandoned with obsolete unsupported implants after Second Sight's financial collapse — set a damaging precedent for the retinal prosthetics market. Argus II was priced at $115,000–$150,000 per device with total treatment costs near $500,000 per patient; limited insurance coverage contributed to its commercial failure. The spectre of inadequate post-market device support from a startup remains salient for both patients and payers evaluating a novel retinal implant. Capital intensity in surgical settings, surgical learning curves, and the absence of established reimbursement codes for GA-indication implants compound near-term uptake constraints. [CM026, CM027, CM028, CM029, CM030, CM031]

2.6 Reimbursement Landscape: US and Europe

Reimbursement is the central commercial risk for PRIMA in both the US and Europe. In the United States, CPT code 67027 covers implantation of an intraocular retinal prosthesis, and Medicare has issued local coverage determinations for retinal prosthetics in end-stage retinitis pigmentosa. However, no national coverage determination exists for geographic atrophy as a retinal prosthetics indication — PRIMA's primary target — meaning initial coverage will depend on MAC-specific LCD decisions and case-by-case prior-authorization requests. CMS's 2026 Physician Fee Schedule set the non-APM participant conversion factor at $33.40/RVU, but payment cuts for facility-based procedures at ambulatory surgical centers reduce procedural economics for implant programs that rely on hospital-based infrastructure. The Argus II precedent — $115,000–$150,000 per device, total per-patient costs near $500,000, and highly variable insurance coverage — demonstrates the commercial fragility of retinal implants with unresolved payer pathways. Science must demonstrate a sustainable device-plus- procedure economics model that payers can accommodate before wide commercial adoption is possible. In Europe, CE Mark is a prerequisite for market entry but does not confer reimbursement. The EU Health Technology Assessment Regulation (EU 2021/2282), entering phased implementation in January 2025, mandates joint clinical assessments for Class IIb and III devices including retinal prosthetics beginning in 2026, adding a pan-European evidence requirement before national HTA bodies render coverage decisions. Each EU member state independently determines coverage; France's HAS, Germany's G-BA, and the UK's NICE have historically been conservative on novel implantable devices with limited long-term outcome data. PRIMA's Science-filed CE Mark application (circa late 2024 / early 2025) is a necessary but insufficient condition for European commercial success. [CM014, CM015, CM016, CM017, CM018, CM019]

2.7 Exhibits

3.1 Competitive Landscape and Tier Structure

Science Corporation's PRIMA implant faces competition across two structural tiers that differ in clinical overlap, timelines, and strategic relevance. The first tier—direct visual prosthetics competition—includes companies building retinal or cortical devices for the same vision-restoration patient populations that PRIMA targets: advanced geographic atrophy from AMD and end-stage inherited retinal diseases. As of mid-2026, this tier is remarkably thin: Pixium Vision SA, the French company that originally developed PRIMA, was liquidated and its assets acquired by Science Corp in April 2024; Retina Implant AG dissolved in 2019; Second Sight's Argus II was commercially withdrawn by 2020; leaving only Bionic Vision Technologies (BVT) in Australia and Cortigent (a Vivani Medical subsidiary) as operationally active direct peers. The second tier—BCI capital and attention competition—includes Neuralink, Synchron, and Precision Neuroscience, which do not compete for the same patients but absorb the same pool of neurotech investor capital and clinical-center training capacity. The BCI sector raised over $960 million in Q1 2026 alone, with capital consolidating around what industry observers call the "Big 6" invasive BCI companies. Science Corp's narrative as a first-to-market vision-restoring BCI company competes with Neuralink's broader technological ambition and Synchron's minimally invasive advantage for limited investor attention and specialized neurosurgical expertise. Understanding both tiers is essential: direct competitors set the clinical evidence bar and precedent commercial failures, while capital competitors define the funding environment and can redirect hospital and payer attention away from vision restoration. Pixium Vision's history is instructive—it developed PRIMA, conducted early clinical trials, and obtained a CE Mark application infrastructure that Science Corp now operates. The acquisition was not merely an IP transaction: it removed a potential near-term competitor and gave Science Corp sole control of the most clinically advanced subretinal photovoltaic platform in existence. No Medicare national coverage determination or FDA premarket approval exists for any permanently implanted BCI device as of June 2026, meaning all competitors in both tiers share an unresolved reimbursement risk. [CP001, CP002, CP026, CP027, CP028]

3.2 Direct Visual Prosthetics Peers — Legacy Failures and Surviving Players

The history of direct retinal prosthetics competition is largely a story of commercial failure, leaving Science Corp's PRIMA operating in a field with fewer active peers than the technology landscape would suggest. Second Sight Medical Products was the first company to achieve FDA approval for a retinal prosthesis—the Argus II epiretinal device—under the Humanitarian Device Exemption (HDE) pathway in 2013, but it generated only approximately $32 million in total revenue from roughly 350 patients globally against approximately $300 million in cumulative investment over two decades before withdrawing the product in 2019-2020. The key failure drivers were a patient population too small to sustain commercial economics, prohibitive total procedure costs (~$500,000 including surgery and rehabilitation), inability to secure broad Medicare Administrative Contractor (MAC) reimbursement coverage, and physician unfamiliarity with a novel surgical procedure. Approximately 350 Argus II patients were left with unsupported implants after the withdrawal, creating a patient-abandonment precedent with lasting ethical and regulatory implications. Second Sight subsequently merged with Nano Precision Medical to form Vivani Medical in 2022, which pivoted to drug-delivery; the neurostimulation business was spun off as Cortigent. Cortigent's Orion visual cortical prosthesis system completed a 6-year early feasibility study in March 2025, with all 6 participants demonstrating safety, reliability, and measurable improvements in visual assessments with less than 4% electrode function loss. Orion stimulates the visual cortex, not the retina, bypassing the entire damaged visual pathway—an important technical distinction, as it can serve patients who have lost both photoreceptor and retinal ganglion cell function, a broader indication than PRIMA's. However, Cortigent requires a craniotomy and is at least one full development phase behind PRIMA on the road to commercialization. Retina Implant AG, the German developer of the Alpha AMS subretinal electrode array (CE-marked 2016, 1,600 electrodes), resolved to dissolve in March 2019, citing inadequate reimbursement across Europe, high regulatory barriers, and clinical outcomes that did not meet patient expectations; it had no acquirer. Bionic Vision Technologies (BVT), an Australian company, is the only remaining active direct retinal prosthetics competitor with credible clinical data. Its second-generation 44-channel suprachoroidal device—implanted outside the retinal layers between the sclera and choroid— showed 97% electrode retention at 2.7 years across 4 clinical trial participants and functional gains in navigation and object detection in 2024-published results, with FDA Breakthrough Device Designation supporting an accelerated regulatory path. BVT's total disclosed funding of approximately $18 million is, however, roughly 27 times smaller than Science Corp's, and it will require substantially more capital to run pivotal worldwide trials and reach commercialization. [CP003, CP004, CP005, CP006, CP007, CP008]

3.3 BCI Capital and Attention Competition — Neuralink, Synchron, Precision Neuroscience

While Neuralink, Synchron, and Precision Neuroscience do not target vision restoration and do not compete for Science Corp's patients, they represent the dominant claimants of the same investor capital pool, clinical-center training resources, and public BCI narrative that determines valuation multiples, press attention, and hospital partnership access. Neuralink is the most capitalized BCI company, having raised a $650 million Series E in June 2025 with total lifetime funding reported at approximately $1.3 billion. Its PRIME study (NCT06429735) enrolled 21 participants across the United States, Canada, and the United Kingdom as of early 2026, targeting tetraplegia patients for cursor-control applications. Despite strong enrollment momentum, Neuralink's first human participant experienced retraction of approximately 85% of electrode threads from brain tissue within weeks of implantation, substantially reducing the device's signal decoding capacity; software updates partially compensated but did not resolve the hardware instability. The US SEC reopened an investigation into Neuralink in late 2024 regarding potential misleading safety claims. Neuralink's outsized media presence—driven by Elon Musk's public profile—generates BCI mindshare that can redirect investor attention and press coverage away from Science Corp's nearer-term and arguably more mature clinical story. Synchron raised $200 million in a Series D round in November 2025, bringing total funding to approximately $345 million, with the capital explicitly directed toward a 2026 FDA pivotal clinical trial for the Stentrode endovascular device. Synchron's approach avoids craniotomy by routing the implant through the jugular vein into the motor cortex blood supply—a minimally invasive advantage that widens the hospital adoption funnel compared to penetrating-electrode alternatives. Synchron targets ALS, paralysis, and stroke patients; its competition with Science Corp is for capital and clinical-center attention, not for the same patients. Synchron is positioning for the title of "first commercially approved BCI in the US" if its pivotal trial succeeds and FDA PMA is granted, a milestone that would compete narratively with Science Corp's potential EU-first commercialization story. Precision Neuroscience closed a $120 million Series D in June 2026, bringing total funding to over $290 million, led by General Catalyst with Microsoft M12 and Coatue Management. Its Layer 7 Cortical Interface is a subdural thin-film electrode array that received FDA 510(k) clearance for up to 30-day neurophysiology applications, making it the only next-generation cortical BCI device with any commercial FDA clearance as of mid-2026. The company had implanted its device in over 85 patients across more than 15 hospital partners and was preparing an IDE submission for a pivotal ALS trial. Like Neuralink and Synchron, Precision Neuroscience does not target visual restoration; its competitive relevance is capital and regulatory attention. Together these three companies absorbed over $1.5 billion in cumulative capital as of mid-2026, creating a competitive funding environment in which Science Corp must articulate a distinct narrative around its regulatory proximity and clinical evidence specificity. [CP013, CP014, CP015, CP016, CP017, CP018]

3.4 Comparative Technical Differentiation — Modality, Invasiveness, and Evidence Maturity

Science Corp's PRIMA differentiates from all active competitors on three converging dimensions: evidence maturity, commercial proximity, and wireless-by-design architecture. Among all retinal and cortical prosthetics companies, PRIMA is the only device with phase II data published in the New England Journal of Medicine demonstrating functional vision restoration—80% of patients showed meaningful visual improvement in the PRIMAVERA trial across 38 to 47 participants—at the time of its CE Mark submission. No competitor in either direct visual prosthetics or the broader BCI tier has reached this combination of journal publication tier, enrollment scale, and regulatory filing simultaneously. PRIMA's photovoltaic wireless design is architecturally distinct: the 378 photovoltaic pixels in the subretinal chip convert near-infrared light delivered through the patient's glasses into electrical stimulation of bipolar cells, entirely eliminating external power connections and transcutaneous leads; this reduces infection risk and simplifies the system compared to wired or battery-recharged alternatives. BVT's suprachoroidal approach places the implant outside the retinal layers, reducing the surgical complexity and retinal trauma risk compared to both epiretinal and subretinal approaches, but the 44-electrode design provides significantly lower theoretical resolution than PRIMA's 378 pixels and has only been tested in 4 subjects. Cortigent's Orion bypasses retinal circuitry entirely by stimulating the visual cortex, which is a genuine technological differentiation that could serve a broader blind population but requires a craniotomy—surgical burden orders of magnitude greater than PRIMA's vitreoretinal procedure. Science Corp acquired all Pixium Vision assets, including clinical trial infrastructure, IP, and the CE Mark application, giving it sole control of the PRIMA platform with no competing claim. The Argus II's CMS reimbursement of $150,000 against a total ~$500,000 procedure cost established a negative commercial precedent that PRIMA will need to explicitly overcome through payer evidence and differentiated outcomes data. PRIMA stimulates bipolar cells in the subretinal space, which preserves inner retinal processing including lateral inhibition—a theoretical resolution advantage over the Argus II's epiretinal ganglion cell stimulation, which bypasses the same circuitry. Synchron's lower surgical burden is a genuine competitive advantage in the broader BCI capital competition, as hospital deployment costs and operator certification time favor endovascular systems; however, this advantage does not apply to retinal surgery, which is a mature procedural specialty with established surgeon training pathways. Precision Neuroscience's 510(k)-cleared Layer 7 electrode establishes a commercial regulatory precedent for a thin-film cortical interface, a data point relevant to future expansion of Science Corp's cortical BCI platform beyond retinal indications. In sum, Science Corp leads on regulatory proximity, evidence maturity, and system elegance, but faces the same commercialization overhead—physician adoption, payer engagement, and long-term support obligations—that destroyed its direct predecessors. [CP029, CP030, CP031, CP032, CP033, CP041]

3.5 Moat Durability, Displacement Risk, and Disconfirming Evidence

Science Corp's competitive moat is real but fragile, and the historic failure rate in this exact competitive niche demands a rigorous adversarial accounting. Three predecessors in direct retinal prosthetics—Second Sight, Retina Implant AG, and Pixium Vision—either failed commercially or were acquired under distress conditions. The Argus II's CE marking and FDA HDE approval did not translate to commercial viability; Retina Implant AG achieved CE marking in 2016 and dissolved three years later; Pixium Vision reached a CE Mark submission stage with PRIMA and ran out of capital before approval. Each failure was driven by some combination of inadequate reimbursement, high procedural cost, low patient volume, and physician adoption inertia—none of which Science Corp has yet demonstrated the ability to overcome at scale. The GAO's 2025 report on brain-computer interfaces explicitly identified the lack of dedicated reimbursement coding, privacy frameworks, and post-market surveillance standards as systemic barriers requiring policy action before widespread BCI commercialization; Medicare currently has no national coverage determination or dedicated coding pathway for permanently implanted BCIs, which means PRIMA would face case-by-case MAC coverage negotiations in the US similar to those that undermined the Argus II. The ethical and regulatory obligation to support implanted patients if Science Corp encounters financial distress is also not resolved; the Argus II abandonment precedent (~350 patients left with unsupported implants) created pressure for policy changes that have not yet materialized. Neuralink's ~$1.3 billion capital base and category-defining media presence could redirect BCI investor flows toward motor/communication applications and away from vision restoration if Neuralink achieves FDA approval faster than Science Corp achieves EU commercial uptake. BVT, despite limited funding, holds FDA Breakthrough Device Designation and is executing a coherent clinical program; if BVT secures a major medtech acquisition or partnership, it could rapidly scale into a credible competitor with manufacturing and distribution support that Science Corp would need years to replicate. Science Corp's implanted-device lock-in is strong at the patient level—the procedural risk of explantation and replacement creates de facto patient retention—but it does not prevent hospital systems from establishing relationships with competing BCI platforms for motor applications, potentially limiting Science Corp's future intrahospital expansion. Surgeon specialization creates a meaningful moat: the vitreoretinal surgical skill set required for PRIMA implantation is well-established across major academic centers, reducing training-curve barriers compared to the novel craniotomy techniques required by cortical competitors. The PMC-published comparative analysis of Second Sight versus Onward Medical concluded that phased commercialization, predicate-technology leverage, and physician familiarity are critical success factors that Second Sight failed to employ—and that Science Corp's management must internalize as it transitions from clinical to commercial mode. In summary, Science Corp's moat is real in the narrow sense of being the only company with NEJM-published evidence and a live CE Mark application for retinal BCI vision restoration, but it is not durable in the structural sense until reimbursement, physician adoption, and post-market support models are proven at commercial scale. [CP034, CP035, CP036, CP037, CP038, CP039]

3.6 Exhibits

4.1 Financing History and Capital Stack

Science Corporation has raised approximately $490 million since its 2021 founding across at least three documented capital events. The most recent is the March 2026 oversubscribed $230 million Series C led by Lightspeed Venture Partners and Khosla Ventures, with additional participation from Y Combinator, IQT (In-Q-Tel), and Quiet Capital; all five were repeat investors, indicating continuity of conviction rather than entry by new validators. The round carried a post-money valuation of approximately $1.5 billion, ranking Science Corp as the second most capitalized dedicated brain-implant startup after Neuralink. Prior to the Series C, the company raised a $104 million convertible note in April 2025 led by Khosla Ventures. The terms of that note—cap, discount rate, and conversion mechanics—were not publicly disclosed, and whether the note converted at the Series C closing or remains as an outstanding obligation is unknown. Individual round sizes for Series A and Series B are not publicly reported, leaving the full round-by-round dilution progression opaque for diligence. The oversubscribed outcome and the rapid cadence from note (April 2025) to equity round (March 2026) signal strong investor demand, but the undisclosed cap table structure prevents independent verification of founder dilution, preference stack depth, or investor liquidation priorities. With $490 million deployed before first commercial revenue, Science Corp's total capital commitment places it firmly in the capital-intensive tier of clinical-stage medtech, where raising funds is a necessary but insufficient condition for commercial success. [CI001, CI002, CI003, CI004, CI005, CI006]

4.2 Capital Intensity and Manufacturing Buildout

Science Corporation's capital intensity is anchored by two mutually reinforcing cost centers: clinical-stage R&D (trials, regulatory submissions, and a growing engineering workforce) and a purpose-built semiconductor fabrication infrastructure. The Science Foundry division occupies a MEMS facility in Research Triangle Park, Durham, NC, originally acquired from French company MEMSCAP in 2022. Science Corp is investing up to $65 million to expand this facility by 57,000 square feet; Durham County commissioners unanimously approved a $930,000 ten-year performance-based incentive award conditioned on meeting job-creation and investment targets. The expansion is expected to create more than 50 new jobs, approximately two-thirds requiring a two-year degree or less, reflecting a manufacturing-floor rather than pure-research workforce composition. Most medtech peers outsource MEMS production; Science Corp's in-house capability is designed to reduce iteration cycles, lower long-run unit costs, and eliminate single-source supply risk. The foundry also offers third-party MEMS services to other medical and BCI device companies, creating a nascent secondary revenue stream. The $65 million foundry capex is incremental to ongoing R&D and clinical expenses, making total annual cash consumption structurally higher than asset-light or outsourced-manufacturing peers. The capex commitment was announced in mid-2024 and is being executed concurrently with the PRIMA commercialization push, indicating simultaneous manufacturing scale-up and clinical progress—a deliberate but capital-intensive strategic choice that requires sustained investor confidence across multiple milestone gates. [CI010, CI011, CI012, CI013, CI032, CI033]

4.3 Revenue Model and Reimbursement Landscape

Science Corporation is pre-revenue in the United States as of mid-2026. PRIMA's commercial launch was targeted for Europe later in 2026 following CE Mark submission; if achieved, this would make Science Corp the first BCI company to place a vision-restoration product on a commercial market. No list price, hospital purchase price, or procedure cost has been publicly disclosed by Science Corp. The nearest historical benchmark is the Argus II (Second Sight), which carried a device-only list price of approximately $145,000, a dedicated CMS reimbursement code (C1849), and total episode costs (device, surgery, and rehabilitation) of $200,000–$300,000. For PRIMA in Europe, Pixium Vision's pre-insolvency pricing was cited in the range of €80,000–€100,000 device-only. U.S. reimbursement is structurally uncertain: Anthem's April 2026 coverage policy explicitly classifies all artificial retinal devices as investigational and not medically necessary for all indications—representing the current default major payer stance rather than an outlier. CMS and FDA jointly announced the RAPID coverage pathway in April 2026, designed to accelerate Medicare coverage of Breakthrough Device-designated products to within 60–90 days post-FDA approval, but PRIMA's Breakthrough Device designation status is unconfirmed in public records as of the research date. New implant procedures typically require custom HCPCS billing codes; the Review of Ophthalmology's 2026 coding update confirms that coverage for artificial retinal prostheses remains payer-specific. The CMS 2026 OPPS final rule brings only modest payment increases for complex intraocular procedures, with APC-average reimbursement around $4,222—far below the expected device purchase cost, reinforcing the reimbursement gap that must be resolved before US commercial adoption can scale. [CI007, CI008, CI014, CI015, CI016, CI017]

4.4 Unit Economics Framework and Private Metric Gaps

Science Corporation has not publicly disclosed any revenue, ARR, gross margin, cost of goods sold, customer acquisition cost, payback period, or net revenue retention. The company remains pre-commercial in the United States, and all unit economics are either pre-determined estimates or proprietary information accessible only under NDA. Industry benchmarks for subretinal devices in pilot manufacturing volumes suggest per-unit COGS of $5,000–$12,000, declining materially with volume automation and supply-chain maturation. Science Corp's vertical MEMS integration may confer a structural COGS advantage once scale is achieved, but the $65 million foundry expansion is a sunk capital outlay that only pays back through device volumes not yet attained. The ABCMoney investment analysis estimates that reaching $500 million or more in annual revenue within 7–10 years would be required to justify the $1.5 billion entry valuation at typical medtech exit multiples, implying thousands of PRIMA procedures annually at $50,000+ per procedure—aggressive but not implausible if reimbursement is established and the AMD addressable population is accessed at scale. Sales cycle economics for PRIMA will differ fundamentally from SaaS metrics: physician training costs, hospital capital equipment procurement cycles, and individual payer coverage determinations will dominate customer acquisition cost. Standard SaaS or marketplace unit economics (NRR, quick ratio, burn multiple) are not applicable to the one-time implant model. No public description of Science Corp's GTM approach for the EU launch has been issued in commercial terms as of mid-2026, making independent assessment of sales efficiency impossible at this stage. [CI014, CI016, CI025, CI026, CI027, CI028]

4.5 Adverse Evidence and Financial Risk Factors

The most salient adverse evidence for Science Corp's financial model is the commercialization track record of its three immediate predecessors. Second Sight Medical Products invested more than $300 million over 24 years in its Argus II retinal prosthetic, generating less than $32 million in cumulative revenue before its abrupt 2019 halt, which left hundreds of implant recipients worldwide without product support. Pixium Vision, the original PRIMA developer, entered judicial liquidation in early 2024 after exhausting its capital; Science Corp acquired its assets under court supervision. Retina Implant AG dissolved in 2019 after Alpha AMS failed to reach commercial scale. Each predecessor had credible clinical science but could not bridge from trial data to commercial revenue at scale. The reimbursement barrier is structural: Anthem's 2026 policy—classifying all artificial retinal devices as investigational and not medically necessary—represents the dominant payer stance until large-scale clinical outcomes data and standardized CPT codes are in place. BCI sector fundraising set a Q1 2026 record at $960 million and Science Corp's oversubscribed Series C confirms current investor appetite, but VC funding is episodic; a clinical setback, regulatory delay, or macro-tightening could compress available runway materially. MedTech Impact Partners warns that the proposed CMS repeal of the NTAP alternative payment pathway by FY2028 would raise the evidence bar for hospital add-on payments, narrowing the reimbursement window for devices not yet covered by that date. With $490 million raised across multiple preferred-share tranches, investor liquidation preferences could materially compress common-stock and founder returns in adverse exit scenarios, and the opaque cap table precludes independent assessment of this risk. [CI017, CI021, CI022, CI023, CI024, CI030]

5.1 PRIMA Implant Architecture and Near-Infrared Image Path

The PRIMA system restores central vision in patients whose photoreceptors have been destroyed by geographic atrophy (GA) while retaining a functional inner retina. The device exploits the eye's optical transparency: an external near-infrared projector delivers both energy and image data through the pupil to a wireless subretinal chip, eliminating batteries and percutaneous cables that plagued earlier retinal prostheses. The implant itself is a thin crystalline silicon photovoltaic array measuring 2 × 2 mm in footprint and just 30 µm thick — approximately half the diameter of a human hair. Its 378 independently controlled pixels are arranged in a hexagonal (honeycomb) grid; each pixel is 100 µm wide and functions as a combined solar cell and electrode. When infrared light at 880 nm illuminates a pixel, it generates a local electric current that stimulates the adjacent bipolar cells in the retina, re-introducing the visual signal pathway that was interrupted by photoreceptor loss. The use of 880 nm wavelength is deliberate: it falls outside the visible spectrum, making it invisible to the patient's surviving photoreceptors and preventing cross-talk with natural peripheral vision. The external hardware consists of three components: (1) sun-lens-equipped glasses with a forward-facing camera that captures the scene and an eye-facing infrared projector; (2) a pocket processor that applies real-time zoom (up to 12×), contrast enhancement, and AI-assisted object-identification algorithms before encoding the result as a NIR pattern; and (3) the projector, which beams patterned 880 nm light precisely onto the subretinal implant. Only illuminated pixels fire, so image resolution is determined by the pixel count on the chip. Because the photovoltaic chip provides power from the incoming light, no implanted battery is required and the device is fully wireless — a key advantage over prior systems such as the Argus II that required percutaneous leads. The technology was originally conceived in 2005 by Daniel Palanker, PhD, at Stanford University, whose lab conducted the first-in-human feasibility trials (NCT03333954, NCT03392324) that Science Corporation later advanced after acquiring all PRIMA intellectual property and clinical trials from Pixium Vision SA in April 2024. [CE001, CE002, CE003, CE004, CE005, CE006]

5.2 Clinical Evidence and Surgical Workflow

The PRIMAvera pivotal study (NCT04676854) is Science Corporation's definitive clinical evidence base for PRIMA. The open-label, multicenter, prospective, baseline-controlled trial enrolled 38 patients older than 60 with advanced GA and baseline visual acuity worse than 20/320 (logMAR ≥ 1.2) at 17 sites across France, Germany, Italy, the Netherlands, Spain, and the United Kingdom. The primary endpoint was a clinically meaningful improvement in visual acuity of at least 0.2 logMAR from baseline to month 12. Among the 32 participants who completed 12-month follow-up, 26 (81%; 95% CI 64–93; p < 0.001) met the primary endpoint. After multiple imputation for the six participants lost to follow-up (three deaths, one withdrawal, two unavailable), the estimated responder rate was 80% (95% CI 66–94). Mean visual acuity gain was approximately 5 ETDRS lines (25.5 letters); the best single-patient improvement reached 12 lines. Of the 32 completers, 27 could read letters, numbers, or words at month 12. Patients who also used the digital zoom and contrast features in the glasses achieved acuity equivalent to 20/42 in some cases. The study was led by Frank G. Holz (University of Bonn), with José-Alain Sahel (University of Pittsburgh) and Daniel Palanker (Stanford) as senior authors; the paper appeared in the New England Journal of Medicine on 20 October 2025 (NEJM 394:232–242; DOI 10.1056/NEJMoa2501396). An accompanying NEJM editorial by Jacque Duncan (UCSF) described PRIMA as "the first treatment to restore vision" in advanced GA. The implantation procedure uses standard vitreoretinal surgical technique. The surgeon performs a three-port 23- or 25-gauge pars plana vitrectomy, induces posterior vitreous detachment if needed, creates a small retinotomy temporal to the fovea, then delivers the PRIMA chip into the subretinal space using a purpose-built custom injector. The chip is centered under the atrophic fovea; endolaser photocoagulation secures the retinotomy edges; a fluid-air or gas exchange may be performed. No external power cable exits the eye. Four to five weeks post-surgery, patients are fitted with the PRIMA glasses and begin a structured visual rehabilitation program with a low vision specialist; it typically takes several months of training to reach peak performance — analogous to the auditory learning required for cochlear implant users. The trial's safety profile is significant but manageable. Twenty-six serious adverse events occurred in 19 of 38 patients (50%). The most frequent was ocular hypertension (6 events in 23% of patients), followed by peripheral retinal breaks (5 patients), subretinal hemorrhage during implantation (3 patients), and full-thickness macular holes (3 patients). Critically, all SAEs were attributed to the implantation procedure alone or to the procedure together with the device; no SAE was attributed to the device alone. Almost all SAEs resolved within two months without sequelae. The Data Safety Monitoring Board formally concluded that the benefits of PRIMA outweigh its surgical risks. [CE008, CE009, CE010, CE011, CE012, CE013]

5.3 Technical Limitations and Next-Generation Roadmap

PRIMA's current commercial specification carries four structural technical limitations that bound the initial patient experience and addressable population. First, vision is black-and-white only: the photovoltaic pixel outputs are binary, and the current software version does not compute grayscale from the scene. Palanker has indicated that a grayscale software upgrade is under development; face recognition, which patients rate as their second-highest priority after reading, requires grayscale gradation. Second, the implant's 2 × 2 mm footprint covers only the central macular zone; peripheral vision is unaffected but prosthetic coverage of the broader retinal surface is not possible with a single chip at current dimensions. Third, the pixel pitch of 100 µm produces coarse prosthetic vision; the estimated theoretical acuity ceiling for a 100 µm pitch device is approximately 20/500 without digital zoom, improving to roughly 20/320–20/200 range with 12× zoom enhancement. Fourth, and most critically for patient selection, PRIMA requires a functional inner retina: the bipolar cell layer — the neurons PRIMA stimulates — must be intact. Patients whose retinal degeneration has progressed to inner retinal atrophy, or those with glaucomatous ganglion cell loss, are not candidates. The next-generation PRIMA chip, currently in pre-clinical development and tested in rats at Stanford, targets pixel pitch of 20 µm with approximately 10,000 pixels per chip. Stanford's Daniel Palanker projects that a 20 µm pitch device could deliver 20/80 baseline prosthetic acuity, and combined with the glasses' electronic zoom, approach 20/20 functional acuity in some conditions. The wireless photovoltaic design also enables future in-situ upgrade: the implant can theoretically be replaced with a higher-resolution chip through a repeat subretinal procedure with minimal incision, unlike tethered devices. Multiple chips can also be implanted in a tiled pattern to cover larger atrophic zones. Science Corporation is also expanding PRIMA to new indications: NCT07266584, a feasibility trial at Sydney Eye Hospital, Australia, is evaluating PRIMA for Stargardt disease and retinitis pigmentosa — both inherited retinal degenerations with macular involvement — with estimated enrollment of five patients and primary completion expected by March 2029. The earlier PRIMAvera trial sample size of 38 patients, while sufficient for CE Mark submission, may be viewed as limited for future label extension requests or reimbursement dossiers beyond the initial GA indication. [CE015, CE021, CE022, CE023, CE039, CE040]

5.4 Platform Technology: Science Eye, LUX, and NYX Chip Families

Beyond PRIMA, Science Corporation is developing a broader neural interface platform whose enabling hardware layers are being built in parallel with the PRIMA commercial push. The Science Eye is Science Corporation's second visual prosthesis program. Unlike PRIMA, which stimulates retinal bipolar cells using a subretinal photovoltaic implant, the Science Eye combines an optogenetic gene therapy — delivered by an adeno-associated virus (AAV) vector targeting retinal ganglion cells (RGCs) in the optic nerve — with a Lightsheet flexible thin-film microLED display inserted directly over the retina. The gene therapy makes RGCs light-sensitive; the microLED array then delivers customized stimulation patterns. A key technical advantage over projector-based approaches is that the flexible film moves with the eye, maintaining a constant pixel-to-cell mapping essential for learning sophisticated visual encodings beyond basic flashes. Science Corporation claims the Lightsheet display achieves approximately eight times the pixel density of an iPhone 13 Super Retina display. The Science Eye targets retinitis pigmentosa and dry AMD where photoreceptors have been destroyed but the roughly one million RGCs per eye remain functional. The program has been formally deferred until after PRIMA achieves a commercial launch somewhere in the world, with animal safety data collection ongoing; no first-in-human trial date has been disclosed. The Science Eye and PRIMA are considered complementary: PRIMA addresses high-resolution central (foveal) vision; the Science Eye could address peripheral coverage, with both systems potentially driven by the same pair of glasses in future configurations. The NYX chip family provides the neural recording layer of the platform: NYX is a low-noise, low-power programmable mixed-signal ASIC for extracellular neural recording, while NYX 512 is a 512-channel fully differential version optimized for high-channel-count brain mapping experiments. The LUX family provides microLED drive capability for optogenetic applications: LUX is a small-form-factor driver designed for single-channel optogenetic stimulation; LUX 2K is an active 2,048-pixel driver; and LUX 16K is a passive 16,384-pixel driver for high-density stimulation arrays. Both chip families are commercially available for research use and are fabricated at the Science Foundry in Durham, NC. The Synapse headstage electronics process, store, and transmit signals between neural probes and the network. The Axon family includes thin-film and silicon neural probes for tissue-contacting electrode arrays. [CE024, CE025, CE026, CE027, CE028, CE029]

5.5 Biohybrid Neural Interface and Developer Ecosystem

Science Corporation's longest-horizon technical program is the biohybrid neural interface. Conventional BCIs use metal or silicon electrodes that cannot form synaptic connections with neurons and typically degrade over years due to glial scarring. Science's biohybrid architecture embeds lab-grown neurons — derived from stem cells and genetically modified to express light-sensitive opsins (optogenetic transduction) — directly into a thin-film electrode array. Once implanted, these neurons extend axons and dendrites into the host brain, forming synaptic connections. A single thin-film device seeded with one million embedded neurons could theoretically form a billion synapses with the brain, providing a bandwidth ceiling orders of magnitude higher than metal electrode arrays. The current biohybrid device incorporates 520 recording electrodes packed into an area approximately the size of a pea. Unlike Neuralink's penetrating electrode approach, Science's device rests on the brain surface (cortical surface placement, not penetrating), potentially reducing glial damage and enabling longer device stability. In 2024, the company published a working paper demonstrating safe implantation and functional optogenetic stimulation of cortical circuits in mice. As of April 2026, Yale Medical School's Murat Günel, chair of the Department of Neurosurgery, has signed on as scientific adviser for the human implant program. The near-term plan is to implant the device's electrode sensor (without embedded neurons) in patients already undergoing major brain surgery — such as craniectomy for brain swelling management — to evaluate safety. Science Corp has stated it does not plan to seek FDA approval for these initial electrode-only sensor trials, arguing the device poses no significant risk. Full clinical trials with embedded neurons are anticipated after 2027. The biohybrid R&D team is led by CSO Alan Mardinly and numbers approximately 30 researchers. On the developer ecosystem side, Science Corporation maintains an active open-source presence at github.com/sciencecorp. The primary developer tool is the Synapse API — a set of protocol buffer definitions enabling Python, TypeScript, and C++ client libraries to discover and communicate with Synapse devices over gRPC. The synapse-python repository had 17 GitHub stars and was updated on June 26, 2026; the broader organization hosts 18 public repositories covering the Synapse API, Galago lab automation stack, NDTP (Neural Data Transport Protocol), and experiment application examples. The open-source ecosystem lowers barriers to research adoption of Science's chip families and creates developer lock-in ahead of commercial products. [CE030, CE034, CE035, CE036, CE037, CE038]

5.6 Science Foundry: Manufacturing and Compliance

Science Corporation owns and operates the Science Foundry, a MEMS and ASIC fabrication facility located in Research Triangle Park, Durham, North Carolina. The facility originated from Science Corporation's acquisition of MEMSCAP's US MEMS foundry assets and team in approximately 2022, giving the company an in-house microfabrication capability that is rare among clinical-stage neural interface companies. The Foundry manufactures Science's proprietary ASIC chip families (NYX neural recording, LUX microLED drivers) and is the intended production facility for the PRIMA photovoltaic subretinal array. In July 2024, Durham County Commissioners unanimously approved a ten-year, $930,000 performance-based economic incentive for Science Corporation's planned facility expansion. The expansion adds approximately 57,000 square feet to the Durham campus, is expected to require a capital investment of $65 million, and is projected to create more than 50 high-wage manufacturing jobs. The facility is targeted for ISO 9001:2015 quality management system certification and FDA current Good Manufacturing Practice (cGMP) compliance. NCBiotech reported that the expansion would support manufacturing for the Science portfolio including the PRIMA implant and advanced neural interface technologies. Vertical integration of the MEMS foundry provides Science Corporation with three strategic advantages: (1) supply chain control for the photovoltaic silicon arrays that are the core of PRIMA — reducing dependency on external foundry partners whose availability and IP tolerance may be uncertain; (2) unit cost reduction leverage as volumes scale, since incremental chip cost at an owned foundry is driven primarily by materials and cycle time rather than margin-loaded external pricing; and (3) the ability to serve selected external biotech and medtech partners as a US-based MEMS foundry, generating non-dilutive revenue and validating the foundry's quality system against external use cases. The Foundry's current production readiness at commercial PRIMA volumes has not been publicly confirmed; pilot-scale manufacturing is the current status. The scale-up to commercial-grade cGMP-certified production for a CE Mark-approved medical device represents a significant operational milestone that has not yet been publicly reached as of mid-2026. [CE031, CE032, CE033]

6.1 Pre-Commercial Landscape: Defining Science Corporation's Customer Universe

Science Corporation occupies a fully pre-commercial position as of June 2026. The company has no paying customers in the conventional sense; every current user of the PRIMA retinal implant system is a clinical trial participant, a patient in a compassionate-access or registry context, or a business partner in a pre-revenue arrangement. This is not unusual for clinical-stage medtech companies, but it is critical context for any commercial assessment: all demand signals today are prospective and contingent on regulatory outcomes that remain unresolved. The customer landscape can be segmented into four distinct roles: (1) patients with advanced geographic atrophy due to AMD, or inherited retinal degeneration, who are eligible for implantation; (2) the implanting vitreoretinal surgeons and academic hospital systems that operate as clinical gatekeepers and eventual commercial purchasers; (3) patient advocacy organizations and registries that aggregate and channel patient demand; and (4) foundry ecosystem partners — early-stage BCI companies that license Science's neural engineering platform. Each segment has a different procurement pathway, different evidence of traction, and a different timeline to revenue. The customer segmentation table below maps these dimensions in full, and the customer journey map illustrates the sequential stages a patient traverses from disease onset to long-term device use, highlighting where Science must deliver commercial infrastructure before it can convert patient demand into revenue. [CU001, CU009, CU010, CU013, CU025, CU040]

6.2 Trial Sites and Implanting Physicians as Gateway Customers

The 17 European clinical trial sites that participated in the PRIMAvera trial (NCT04676854) represent the most developed layer of Science's early customer network. These sites — spanning France, Germany, Italy, the Netherlands, and the United Kingdom — collectively enrolled 38 patients aged 60 or older with advanced dry AMD and geographic atrophy. The lead investigator was Dr. Frank Holz of the University Hospital Bonn, who co-authored the pivotal NEJM publication in October 2025. In the UK, Moorfields Eye Hospital served as the sole trial site, enrolling five patients under the direction of Dr. Mahi Muqit, senior vitreoretinal consultant at Moorfields and the Institute of Ophthalmology at UCL. Dr. Muqit described the PRIMA chip operation as safely performable "by any trained vitreoretinal surgeon in under two hours," a deliberate positioning designed to support broad clinical scalability. In the United States, the University of Pittsburgh Medical Center (UPMC) Vision Institute led by Dr. José-Alain Sahel was the first US center to implant PRIMA in a clinical feasibility study, positioning UPMC as the anchor US commercial site for any FDA-cleared launch. Science Corporation reports a total of 18 clinical partnerships established as of its patient registry announcement, a number that encompasses the PRIMAvera European sites and the expanding US feasibility network. These trial sites will likely serve as the initial commercial customers upon regulatory approval, transitioning from investigator- sponsored trial roles to device-purchasing hospital departments — provided reimbursement infrastructure exists at the time of launch. [CU002, CU006, CU007, CU008, CU013, CU017]

6.3 Patient Registry and Advocacy: Channeling Latent Demand

Science Corporation launched a formal patient registry in 2025-2026 covering individuals diagnosed with age-related macular degeneration, retinitis pigmentosa, and Stargardt disease. This registry serves multiple commercial functions simultaneously: it generates a qualified pipeline of future PRIMA patients, informs clinical trial design for expanded indications, and creates a direct communication channel between the company and the patient community. Participation is free, privacy-respecting, and reversible, with participants retaining full data control. The registry tracks not only traditional clinical metrics such as best-corrected visual acuity but also functional outcomes — reading ability, face recognition, and navigation — that Science has identified as the most meaningful indicators of patient benefit. Registry participants receive priority access to future clinical trials and emerging device generations. Science Corp states that approximately five million people worldwide are affected by end-stage atrophic AMD for which no vision-restoring therapy currently exists, representing the primary addressable patient pool. The eligibility threshold is strict: patients must be 60 years or older, have advanced dry AMD with geographic atrophy, and present with best-corrected visual acuity of 20/400 or worse in the study eye, with a confirmed central scotoma. This narrow eligibility funnel, combined with the need for retained peripheral vision and absence of other confounding ocular conditions, is expected to yield a substantially smaller commercial-ready population than the headline AMD figure suggests. Patient advocacy organizations have been engaged; the Macular Society (UK) described the PRIMA results as "encouraging" and stated it was watching closely for UK regulatory approval and potential NHS availability. [CU003, CU009, CU010, CU011, CU012, CU014]

6.4 Commercial Adoption Pathway: Regulatory Gates and Reimbursement Gaps

Science Corporation submitted its CE mark application for PRIMA to the European Union and its IDE/PMA-equivalent to the FDA concurrently, as confirmed in the company's own patient registry announcement in June 2026. Industry analysts and news coverage consistently identify Germany as the anticipated first commercial market, given its regulatory framework for new devices and historical precedent for early-access neurotechnology approvals. CE mark approval was widely anticipated by mid-2026, though no approval had been publicly announced as of the reporting date. In the UK, Dr. Muqit confirmed a likely additional approval timeline of one to two years post-CE mark, requiring sequential approvals from MHRA, NICE health technology assessment, and NHS England commissioning — a three-stage gatekeeping process typical for high-cost implantable devices. The US pathway is longer still: PRIMA carries an FDA Breakthrough Device designation (inherited from the Pixium acquisition), which accelerates review but does not bypass the full PMA pathway. Critically, as of June 2026, no US Medicare reimbursement code, national coverage determination, or local coverage policy exists for PRIMA. The American Society of Retina Specialists' review of 2026 Medicare payment proposals did not identify a specific code for the PRIMA system; new implantable devices typically require an FDA clearance event followed by CPT/HCPCS code assignment and subsequent CMS review before any covered clinical use begins. This sequence creates a potential multi-year gap between US regulatory clearance and actual reimbursed commercial deployment. [CU019, CU020, CU021, CU022, CU023, CU024]

6.5 Foundry Ecosystem: B2B Customers of the Science BCI Platform

Science Corporation announced on February 20, 2026, a multi-year BCI Ecosystem partnership with Neurosoft Bioelectronics, a Geneva-based neural data company that develops ultra-soft cortical probes for tinnitus, epilepsy, and other neurological disorders. Neurosoft's probes had already been deployed in a dozen human patients prior to the partnership announcement. Under the Science Ecosystem model, partners gain access to Science's complete clinical-grade neural recording technology stack — including recording electronics, neural probes, software, and application tooling — for a fraction of the cost of developing equivalent infrastructure independently. Science estimates that building a full-stack clinical-grade BCI platform from scratch costs $75 million to $100 million and takes multiple years; the Ecosystem partnership enables first-in-human trials for under $5 million in a fraction of the time. Max Hodak, Science CEO, described the Neurosoft deal as "the first of many" expected partnerships, positioning the Science Ecosystem as a platform business model analogous to foundry services in the semiconductor industry. These ecosystem partners are a distinct B2B customer category from the patient/hospital channel: they purchase access to Science's engineering infrastructure rather than the PRIMA device itself, and they target neurological indications beyond Science's in-house programs. The revenue model for ecosystem deals involves multi-year, multi-million-dollar contracts, though specific financial terms have not been disclosed. The customer proof matrix below provides an evidence-quality comparison across all four customer segments. [CU025, CU026, CU027, CU028, CU029]

6.6 Adoption Barriers, Adverse Evidence, and Concentration Risk

Several structural barriers temper the optimistic demand narrative. First and most significantly, PRIMA generates zero revenue as of June 2026: all "customers" are clinical trial participants or pre-revenue partners, and no commercial transaction has occurred. Second, the device's adverse event profile warrants scrutiny: in the PRIMAvera trial, 26 serious adverse events occurred across 19 of 38 patients (50% SAE incidence at the patient level), including retinal tears, increased intraocular pressure, retinal detachment, and proliferative vitreoretinopathy. While 95% of these events resolved within two months, the treated eyes also showed a larger increase in geographic atrophy area compared to untreated control eyes, raising unresolved questions about device-related acceleration of the underlying disease. Third, the near-term commercial footprint is narrowly concentrated at elite academic vitreoretinal centers. The PRIMAvera trial required 17 specialized European sites and one US center; not all vitreoretinal surgeons have the subretinal implantation skills and post-operative rehabilitation infrastructure required. Broad geographic access is therefore structurally limited by training and center certification requirements, creating a bottleneck that persists even after regulatory approval. Fourth, Science's patient eligibility criteria are narrow: candidates must be 60 or older with complete central vision loss and must retain residual peripheral vision — a profile that screens out many AMD patients. Fifth, the entire US commercial path is stalled until both FDA clearance and Medicare reimbursement are secured, a sequence that may extend well beyond the CE-mark timeline in Europe. These barriers collectively mean that Science's commercial ramp, even in an optimistic scenario, will be slow, dependent on a handful of specialist centers, and initially confined to single-country European markets with the most favorable reimbursement environments. [CU001, CU023, CU030, CU031, CU032, CU033]

6.7 Exhibits

7.1 Regulatory Approval Risk: FDA PMA and EU CE Mark

Science Corporation's near-term commercial viability depends entirely on two parallel regulatory outcomes: FDA Pre-Market Approval for the US market and CE mark confirmation for the European market. Neither approval is guaranteed, and both carry timing uncertainty that could delay commercialization by one to three years beyond current projections. FDA Breakthrough Device designation (secured 2023) accelerates interactions and review scheduling, but does not reduce the evidentiary threshold for safety and effectiveness. The FDA PMA pathway for a Class III implantable device typically takes 180 days for substantive review after filing, and the Agency reserves the right to issue Additional Information requests that can extend this by 12 months or more. Science's CE mark application, submitted to BSI with approximately 60 gigabytes of documentation in June 2025, is under EU MDR review and a decision has not been confirmed as of June 2026. The EU Medical Device Regulation (2017/745) imposes post-market clinical follow-up requirements on Class IIb implants that Science must design into its commercial surveillance program before approval. The FDA and CMS jointly announced the RAPID Coverage Pathway in April 2026, which allows Breakthrough Devices to receive Medicare coverage concurrently with FDA approval rather than waiting the typical 6-18 months post-approval. This substantially mitigates reimbursement tail risk but requires Science to proactively engage with both agencies. The Humanitarian Use Device designation request, if granted, would allow PRIMA commercialization under a 8,000-patient annual ceiling with a reduced profit-limitation framework, providing a bridging mechanism between clinical trial and full commercial scale. Intellectual property risks are modest given the Palanker Lab patent portfolio acquired via Pixium, but freedom-to-operate validation remains an open diligence item for the subretinal photovoltaic pixel design space. [CR001, CR002, CR003, CR004, CR005, CR006]

7.2 Clinical Safety and Efficacy Durability Risk

The PRIMAvera pivotal trial reported 26 serious adverse events in 19 of 38 patients — a 50% incidence rate — with four classified as severe: macular hole, retinal detachment, proliferative vitreoretinopathy, and ocular hypertension. Twenty-one of the 26 SAEs occurred within the first two months post-implant, consistent with a surgical-phase event profile rather than a chronic device failure mode. The Science Corp Data Safety Monitoring Board reviewed the 24-month data and recommended trial continuation without protocol modifications, a signal of acceptable benefit-risk balance for the DSMB. However, two specific signals will receive scrutiny in any FDA review. First, geographic atrophy area increased by 8.5 mm² in PRIMA-implanted eyes versus 2.5 mm² in fellow control eyes over 24 months — a statistically significant difference that Science attributes to the surgical trauma of subretinal space entry and not to the photovoltaic chip itself. While visual acuity and letter-reading gains persisted despite this anatomical progression, the mechanism requires explanation in the PMA submission. Second, no long-term implant durability data beyond 36 months exists for any commercial subretinal photovoltaic device. PRIMA's second-generation chip design, which improved pixel density and biocompatibility, may effectively reset the durability clock relative to any pre-clinical or earlier cohort data. Analogous risks are visible in adjacent BCI development: Neuralink's first human trial recorded wire retraction from brain tissue in its initial implant in May 2024, illustrating that biotic-abiotic interface stability at long durations remains an open challenge across implantable neural devices. Science's subretinal placement differs mechanically from cortical arrays, but the fundamental challenge of maintaining a stable, biocompatible interface over decades is shared. Any FDA Additional Information request on GA progression or implant durability could add 12-24 months to the review timeline and require supplemental trial data. [CR008, CR009, CR010, CR011, CR012, CR013]

7.3 Reimbursement and Commercial Adoption Risk

The United States Centers for Medicare and Medicaid Services has no dedicated CPT code, coverage determination, or payment framework for implantable subretinal prostheses as of June 2026. Private payers typically follow CMS's lead: Anthem Blue Cross's DME.00052 policy already classifies brain-computer interface rehabilitation devices as investigational and not medically necessary, regardless of FDA review status. The GAO's 2025 BCI technology assessment (GAO-25-106952) found that BCI developers had historically found it difficult to engage with CMS about their devices, and that patients who received implants during clinical trials faced device explantation when trial funding ended — a structural risk that insurers and hospitals weigh when deciding whether to adopt a novel implantable platform. The April 2026 RAPID Coverage Pathway directly addresses this issue by allowing simultaneous FDA approval and Medicare coverage determination for Breakthrough Devices, but the pathway is new, has not yet been tested for any implantable visual prosthetic, and requires proactive co-engagement with the FDA and CMS that Science must initiate during the pre-submission phase. The absence of PRIMA commercial pricing in any public document makes it impossible to assess whether Science Corp's target price point is compatible with what hospitals, HTA bodies, or national payers will accept. Cochlear implant analogy suggests a $30,000-$100,000 device cost; retina-specific payer skepticism may set the acceptable ceiling lower. In Europe, Science must navigate country-by-country AMNOG and HTA processes for reimbursement after CE mark — a process that has typically taken 12-36 months for novel implantable devices. The downstream private-payer vacuum created by CMS inaction amplifies this risk: without a US coverage signal, European payers have no precedent to reference when setting reimbursement rates, and Science's commercial launch timeline becomes dependent on whichever market's payer infrastructure materializes first. [CR016, CR017, CR018, CR019, CR020, CR021]

7.4 Manufacturing, Operational, and Quality Systems Risk

Science Corporation is building a manufacturing facility in Durham, North Carolina with a $65 million investment announced in 2024, targeting 150+ new jobs in life-sciences manufacturing. The PRIMA chip is a photovoltaic CMOS/MEMS device whose fabrication relies on semiconductor foundry processes; Science's in-house foundry business (offering custom chip manufacturing to external BCI clients) serves dual roles as both a revenue diversification vehicle and the primary manufacturing platform for PRIMA arrays. The 21 CFR Part 820 Quality System Regulation and its international counterpart ISO 13485:2016 require comprehensive design controls, process validation records, and corrective-action systems for implantable device manufacturers. Science's CE mark submission reportedly includes approximately 60 gigabytes of quality system documentation, suggesting an advanced quality management posture — but no public confirmation of ISO 13485 certification for the Durham facility has been identified in research conducted for this chapter. A manufacturing non-conformance finding during a pre-approval inspection could trigger a production hold or require a PMA supplement, potentially delaying commercial launch by 12-24 months. Supply chain concentration in the CMOS/MEMS fabrication supply chain — particularly for the specialty photovoltaic pixel processes that distinguish PRIMA from standard CMOS — represents an additional operational risk not fully mitigated by the in-house foundry capability. The hardware foundry's external client business may also compete for fab capacity and engineering talent during the critical PRIMA commercial ramp period. [CR023, CR024, CR025, CR026, CR027, CR028]

7.5 Strategic Concentration, Key-Person, and Platform Distraction Risk

Science Corporation operates four distinct program areas — PRIMA retinal implant, biohybrid neuroscience, hardware foundry, and Vessel (wearable BCI hub) — with approximately 150 employees as of March 2026. PRIMA is the sole program with clinical data and a near-term revenue path; all other programs are pre-clinical or pre-revenue. This concentration means that regulatory delay, clinical setback, or commercial failure in PRIMA would eliminate the primary revenue thesis without an alternative near-term fallback. Max Hodak, co-founder of Neuralink and CEO of Science Corp, is the company's primary public face and chief strategic architect. TIME Magazine named Hodak to its 2026 TIME100 Health list, underscoring his profile — but public succession plans and key-person insurance arrangements have not been disclosed. The departure of Hodak or Chief Scientific Advisor Jacques-Alain Sahel (one of the world's leading retinal prosthetics researchers and a co-author on key PRIMA clinical papers) would likely impair regulatory credibility, clinical network access, and investor confidence. The biohybrid brain sensor program targets first-in-human implantation before 2027, per comments from Yale collaborator Murat Günel; while scientifically compelling, this program requires dedicated engineering and clinical trial infrastructure that competes with PRIMA development for talent and management attention. Science Corp's $490M total funding and estimated $20-30M annual burn rate imply a 7-8 year runway — sufficient for a 3-year regulatory timeline — but capital intensity of commercialization, including surgeon training programs, post-market surveillance infrastructure, and US facility build-out, may compress this estimate. The Vessel platform adds a fourth regulatory and commercial pathway that further dilutes organizational focus at a stage when PRIMA urgently requires concentrated execution. [CR029, CR030, CR031, CR032, CR033, CR034]

7.6 Sector Precedent, Structural Risk, and Kill Criteria

The retinal prosthetics sector has a consistent record of commercial failure despite clinical proof of concept. Second Sight Medical Products abandoned its Argus II bionic eye product line in 2019, leaving more than 350 patients with unsupported implants; the case of Barbara Campbell — whose Argus II failed inside a New York City subway station, rendering her suddenly blind in an already dangerous environment — became the exemplar of what happens when a medtech company exits without a device-continuity plan. Pixium Vision entered Paris Commercial Court liquidation in 2024 and was acquired by Science for approximately €4 million, demonstrating that even CE-marked devices cannot generate sufficient commercial revenue to sustain a standalone company without reimbursement support. Retina Implant AG discontinued operations after 16 years of development, citing an innovation-hostile regulatory and reimbursement climate. Science Corp's PRIMA design differs fundamentally from these predecessors — subretinal photovoltaic stimulation targeting partially sighted patients rather than fully blind subjects, with no external wire and a dramatically simpler surgical technique — but the structural risks of payer skepticism, limited long-term durability evidence, and small addressable patient populations are shared. The GAO flagged ethical and privacy risks in BCI technology — including data security, cognitive liberty, and the risk of "neurosurveillance" — as among the 12 most pressing policy challenges for the sector; these concerns are intensified by the fact that PRIMA connects to a wearable AI-processing unit that captures continuous visual field data. An institutional payer catch-22 compounds these structural risks: limited commercial revenue depresses the clinical evidence base required for positive coverage determinations, while coverage gaps prevent the commercialization needed to generate that evidence. Monitorable kill criteria include: (1) FDA refuses to file the PMA or issues a non-approvable letter; (2) the RAPID pathway CE mark or CMS coverage determination is delayed beyond 2029; (3) a third severe SAE type emerges in the extended PRIMAvera data; (4) Hodak departs without a disclosed succession plan; and (5) Series D funding cannot be raised within 24 months of Series C at a flat or up-round valuation. [CR037, CR038, CR039, CR040, CR041, CR042]

7.7 Exhibits

8.1 Valuation Context and Round Terms

Science Corporation closed its Series C in March 2026 at a $1.5 billion post-money valuation, raising $230 million in what the company described as an oversubscribed round — a demand signal that implies the company had the ability to raise more or turn away capital. Investors included all five repeat participants from earlier rounds: Lightspeed Venture Partners, Khosla Ventures, Y Combinator, IQT (In-Q-Tel), and Quiet Capital. Repeat-only investor composition removes the independent validation that a new lead investor might provide, but also signals sustained conviction from sophisticated deeptech investors who have observed the company's progress firsthand. Total capital raised since the 2021 founding is approximately $490 million, placing Science among the best-capitalized private BCI companies globally behind Neuralink. The previous financing event was a $104 million convertible note led by Khosla in April 2025; neither the note's conversion cap, discount rate, nor conversion mechanics were publicly disclosed. Whether the note converted at Series C close or remains as outstanding obligations that affect the effective post-money valuation calculation is unknown. The full cap table structure — including individual investor ownership percentages, preference stack depth, participation rights, and liquidation waterfall — has not been publicly disclosed, making independent verification of the $1.5B figure's economic meaning to each stakeholder impossible without NDA-protected access. The oversubscribed outcome in a quarter when overall medtech VC volume cooled from its 2025 peak is a positive signal, but the absence of independent pricing discipline (no new lead investor, no disclosed valuation methodology) limits the information content of the price mark. [CV001, CV002, CV006, CV007, CV008, CV009]

8.2 Investment Thesis and Anti-Thesis

The bull case for Science Corporation rests on a coherent alignment of clinical, regulatory, and strategic factors. PRIMA's NEJM-published pivotal trial result (80–84% of patients achieving meaningful visual acuity improvement in 47 patients across 17 EU and US sites) represents the highest-quality clinical evidence ever published for an implantable vision-restoration device. CE Mark application was submitted to BSI in June 2025 with approximately 60 gigabytes of documentation, and a mid-2026 decision would make Science Corp the first BCI company to place a product on market anywhere — a first-mover premium that justifies a valuation above pure DCF fundamentals in highly competitive platform markets. The FDA Breakthrough Device designation enables enhanced FDA engagement and, combined with the April 2026 RAPID Coverage Pathway, creates a simultaneous FDA approval and Medicare coverage mechanism that removes the historical 12–18 month post-approval reimbursement gap. The in-house MEMS foundry provides manufacturing differentiation and a platform optionality angle that no other retinal prosthetics company has offered. The anti-thesis is equally grounded. Science Corp is pre-revenue globally. All three CE-marked predecessor retinal prosthetics companies — Second Sight (Argus II), Pixium Vision (Prima Alpha/PRIMA), and Retina Implant AG (Alpha IMS) — achieved regulatory clearance but failed commercially, with the sector's combined loss of hundreds of millions in investor capital. Anthem's 2026 policy classifies all artificial retinal devices as investigational and not medically necessary, representing the current default US private-payer stance before any Science Corp commercial presence. EU reimbursement after CE Mark requires country-by-country HTA processes typically taking 12–36 months in key markets. Platform distraction risk from biohybrid neural interface, Vessel, and the foundry business divides management and capital at a stage requiring concentrated PRIMA execution. Private-market mark inflation in the 2025 VC cycle, combined with an oversubscribed round from repeat-only investors, raises questions about whether the $1.5B mark reflects fundamental value or an optimistic cycle-peak pricing event. [CV013, CV014, CV015, CV016, CV017, CV018]

8.3 Comparable Valuation Analysis

Stage-adjusted medtech logic — not SaaS multiples — is the correct valuation framework for Science Corp. For commercial medtech hardware companies in 2026, EV/Revenue multiples are 3.5–5.5x and EV/EBITDA multiples are 11–14x (per healthcare.digital's 2026 M&A matrix and Equidam's 2026 industry EBITDA survey). Applied to an assumed first-full-year EU revenue of $50M–$80M in 2027–2028 at a 35–40% gross margin, these multiples yield an enterprise value range of roughly $175M–$440M — well below $1.5B. The valuation premium is supported by three non-multiple factors: (1) first-mover and winner-take-most dynamics in BCI vision restoration; (2) platform optionality from biohybrid, foundry, and Science Eye programs; and (3) Bain-tracked 2025 medtech M&A activity reaching $97.6 billion, with strategic buyers paying 15–25x EBITDA for category-leading devices. The BCI peer set provides the most directly relevant comps: Neuralink at $9.6B post-Series E (May 2025, $656.5M raised, 6x the Science Corp valuation), Synchron at approximately $1B post-Series D (November 2025, $345M total raised), and Precision Neuroscience at approximately $500M post-Series C (December 2024, $155M total raised). Science Corp's $1.5B at $490M total raised compares favorably on capital efficiency: Synchron's implied ~$1B post-$345M total is roughly 2.9x total raised, whereas Science's $1.5B on $490M is 3.1x — nearly equivalent, but Science Corp has substantially better clinical evidence and a clearer near-term commercial path. The ophthalmology M&A comps are less useful because they involve established revenue-generating platforms (Cencora's $4.6B acquisition of Retina Consultants of America at 15–23x EBITDA), but they do confirm that strategic buyers in retina have been willing to pay high multiples for differentiated platforms. The historical retinal prosthetics failures (Second Sight peak market cap ~$100M; Pixium acquired for ~€4M; Retina Implant AG discontinued) define the sector's downside scenario rather than its exit multiple. [CV003, CV004, CV005, CV023, CV024, CV025]

8.4 Scenario Analysis and Probability-Weighted Valuation

Three scenarios frame the valuation range for Science Corp as of June 2026. The bull case assumes CE Mark approval in Q3 2026, German commercial launch with early-access reimbursement by Q4 2026, 10–15 procedures per quarter ramp at €80K–€90K device ASP, RAPID pathway enabling US Medicare coverage within 90 days of FDA approval (2027–2028), and foundry/biohybrid platform optionality contributing terminal value. Under this scenario and a 7–10x forward revenue multiple on 2028 projected revenues of $120M–$200M, the implied enterprise value is $2.5B–$3.5B, representing solid risk-adjusted returns from the $1.5B entry. The base case assumes CE Mark in H2 2026 but a 12–18 month EU HTA process in Germany and France before meaningful reimbursement, a US FDA decision in 2029, and cautious hospital uptake reflecting the sector's prior failure history. Base case first-year revenue $30M–$50M at a 4–6x forward multiple yields implied EV of $700M–$1.1B — below the March 2026 entry valuation. The bear case assumes CE Mark delay beyond 2026, EU reimbursement fails to establish within 2 years (following the sector precedent), FDA further delayed past 2030, and a down-round or distressed strategic exit is required. Bear case implied value is $150M–$400M, representing substantial capital loss for Series C investors. Probability-weighting these scenarios — 30% bull, 50% base, 20% bear — yields an expected value of approximately $1.0B–$1.25B, which is 17–33% below the March 2026 entry price of $1.5B. This negative expected value gap is partially offset by optionality value not captured in the DCF scenarios: the biohybrid program, the foundry business, and the Science Eye platform create upside scenarios not modeled in the revenue-based valuation. For a fund with a 7–10 year horizon and a portfolio construction that can absorb binary FDA risk, the valuation is defensible but not compelling at $1.5B; at $1.0B–$1.2B entry it becomes attractive. [CV027, CV028, CV029, CV030, CV031, CV037]

8.5 Exit Readiness and Strategic Pathway

Science Corporation is not IPO-ready as of mid-2026 by standard public-market criteria: it has no revenue, no disclosed unit economics, and is pre-commercial in all markets. The IPO window that reopened for medtech with EdgeMedical's $2.2B surgical robotics listing in January 2026 requires at minimum commercial revenue and visible profitability trajectory. A realistic IPO window for Science Corp is 2028–2031, conditional on EU commercial launch execution, US FDA approval, and a minimum of 12–18 months post-approval commercial traction generating $50M+ annualized revenue. The more likely near-term exit pathway is strategic acquisition by a large medtech or pharma platform. Strategic acquirers with the strongest strategic fit include Medtronic (neurology portfolio), Boston Scientific (which acquired Penumbra for $14.5B in January 2026 to build neuro/vascular capabilities), Johnson & Johnson MedTech (retina and device platform), and Abbott (diagnostics and neuromodulation). A strategic acquisition would likely be triggered by FDA approval and at least one year of commercial revenue, implying a 2029–2031 transaction window. The absence of secondary market liquidity data, disclosed SPAC discussions, or investment bank engagement makes it impossible to assess the company's current exit posture. Any acquirer due diligence would need to resolve the preference stack and convertible note treatment to determine actual proceeds distribution to various stakeholder classes. [CV032, CV033, CV034, CV035, CV036]

8.6 Recommendation and Final Diligence Asks

Recommendation: TRACK (research-more posture). The investment thesis is coherent and partially de-risked by NEJM-quality clinical evidence, a credible first-mover commercial path, and a strong investor syndicate. The anti-thesis is structural: sector base rate of commercial failure, zero revenue disclosure, undisclosed cap-table preference stack, and a $1.5B entry that prices in partial bull-case execution. The risk rating is HIGH — binary regulatory outcomes dominate the valuation, and the predecessor sector failure rate (0 for 3 CE-marked retinal prosthetics companies achieving commercial sustainability) cannot be dismissed. Confidence is MEDIUM — the clinical evidence is strong, the regulatory process is advanced, but commercial execution evidence does not yet exist. At the $1.5B entry price, the risk/return is marginal given the expected-value gap. Thesis-break triggers include: CE Mark rejection or RFI delaying approval past Q2 2027; EU launch revenue tracking below 5 procedures per quarter at 6 months post-launch; FDA issuing a not-approvable letter or requesting a new pivotal trial; or any two founding executives departing within 12 months. Diligence should prioritize the cap table, preference stack, and convertible note treatment to assess effective entry economics before any investment commitment. CE Mark approval outcome and Germany first pricing/reimbursement data are the single highest-information near-term catalyst. The RAPID pathway engagement timeline with FDA/CMS and any confirmed Breakthrough Device designation from the FDA primary record should be independently verified. A revised entry valuation of $1.0B–$1.2B (at next round or secondary) would substantially improve the expected-value math. [CV039, CV040, CV041, CV042]

8.7 Exhibits